A Passion for Science and a Commitment to Dermatology

Dermavant Sciences, a subsidiary of Roivant Sciences, is a clinical-stage biopharmaceutical company committed to fostering unprecedented change and unparalleled impact in immuno-dermatology. We’re doing this by thinking differently, pushing the boundaries of science and partnering with providers in new ways—all with one goal: transforming the lives of millions of patients with skin diseases.

Dermavant Voices: Patient-Focused Innovation

“The ability to transform lives”

Todd Zavodnick
Chief Executive Officer

“A passion for helping people”

Philip M Brown, MD, JD
Chief Medical Officer

“Fundamentally changing the lives of patients”

David Rubenstein, MD, PhD
Chief Scientific Officer

DERMAVANT. Innovating. Pioneering. Transforming.

We Will Transform Dermatology.

VIEW CORPORATE FACT SHEET

Latest News

November 17, 2020

Dermavant Named One of Fortune® Magazine’s 2020 ...

October 27, 2020

Dermavant’s Pivotal Phase 3 PSOARING Data for Ta ...

October 22, 2020

Dermavant Announces Presentation of Tapinarof Pivo ...